-31% TLIK.F Arzneiwerk AG VIDA (XETRA) after hours 16 Feb 2026: key watchpoints

The TLIK.F stock plunged 31.05% in after-hours trading on 16 Feb 2026, closing at €0.26 on XETRA. This sharp move followed heavy selling that lifted volume to 1,784 shares, above the 50-day average of 664. Investors should note weak fundamentals, a negative EPS and a recent D+ company rating that connect to the price fall.

TLIK.F stock: after-hours price action and immediate trigger

Arzneiwerk AG VIDA (TLIK.F) fell €0.12 to €0.26 in after-hours trade on 16 Feb 2026. The drop represents -31.05% versus the previous close of €0.38. Volume spiked to 1,784 shares, about 2.7x the average, indicating sellers dominated the session.

TLIK.F stock: fundamentals and valuation snapshot

TLIK.F shows an EPS of -0.11 and a PE of -2.36, reflecting negative earnings. Market cap stands at €1,620,689.00 with 6,233,420 shares outstanding. The 50-day average price is €0.31 and the 200-day average is €0.36, both above the current price, signalling longer-term weakness.

TLIK.F stock: technicals, liquidity and trading metrics

On technicals the RSI sits at 47.61, near neutral, while ADX at 33.43 shows a strong trend. Bollinger bands range €0.20–€0.37, and ATR is €0.05. Relative liquidity is thin; average volume is 664 and current volume is 1,784, so price moves can be large on modest orders.

TLIK.F stock: Meyka AI grade and analyst context

Meyka AI rates TLIK.F with a score out of 100: 62.61 (B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. External rating on 13 Feb 2026 gave a D+ (Strong Sell), creating mixed signals between models and third-party ratings.

TLIK.F stock: Meyka AI’s forecast model projects and implied moves

Meyka AI’s forecast model projects a monthly price of €0.27 and a quarterly price of €0.51 for TLIK.F stock. Versus the current €0.26, the monthly forecast implies +3.05% upside and the quarterly implies +94.66% upside. Forecasts are model-based projections and not guarantees.

TLIK.F stock: sector context, risks and near-term opportunities

Arzneiwerk AG VIDA operates in Healthcare distribution, a sector with steadier averages than this small-cap stock. Key risks include thin liquidity, negative cash flow per share, and an effective current ratio of 0.04. Opportunities depend on securing stable supply contracts for rare medicines and improving operating cash flows.

Final Thoughts

TLIK.F stock posted a severe after-hours drop of -31.05% to €0.26 on 16 Feb 2026 on XETRA, driven by outsized selling in a low-liquidity name. The company posts EPS -0.11, negative cash flow per share, and a weak current ratio, which explain part of the decline. Meyka AI rates TLIK.F with a score out of 100 at 62.61 (B, HOLD), while a third-party rating on 13 Feb 2026 recommended Strong Sell. Meyka AI’s forecast model projects €0.27 monthly and €0.51 quarterly targets, implying +3.05% and +94.66% moves respectively from the current price of €0.26. Given thin trading, negative fundamentals, and mixed ratings, short-term risk remains elevated. Active traders may watch the €0.20–€0.37 Bollinger band range, while longer-term investors should seek stronger cash flow improvement and clearer contract wins before adding exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.